Table 5.
Tumor characteristics in cases with total cases and rare alleles
| Characteristic | 2006 AMC* |
2006 NCC** |
2005 AMC* |
This study | Rare alleles |
χ2-value*** (P value) |
|---|---|---|---|---|---|---|
| Age | ||||||
| Mean | 63.9 (42-78) | 64.1 (46-80) | 64.3 (40-83) | 67.9 (50-88) | 64.7 (55-81) | |
| T-stage | ||||||
| T1 | 0 (0.0%) | 0 (0.0%) | 130 (41.0%) | 42 (13.2%) | 0 (0.0%) | 6.0132 (df = 3) |
| T2 | 116 (62.4%) | 52 (63.4%) | 183 (57.7%) | 139 (43.8%) | 3 (42.9%) | P = 0.1110 |
| T3 | 68 (36.6%) | 29 (35.4%) | 4 (1.3%) | 95 (30.0%) | 1 (14.3%) | |
| T4 | 2 (1.1%) | 1 (1.2%) | 0 (0.0%) | 41 (12.9%) | 3 (42.9%) | |
| N-stage | ||||||
| N0 | 182 (97.8%) | 45 (91.8%) | 291 (91.8%) | 265 (85.8%) | 3 (42.9%) | 6.7334 (df = 1) |
| N1 | 4 (2.2%) | 4 (8.2%) | 26 (8.2%) | 44 (14.2%) | 4 (57.1%) | P = 0.0095 |
| M-stage | ||||||
| M0 | 158 (84.9%) | 45 (91.8%) | 280 (88.3%) | 247 (75.5%) | 3 (37.5%) | 4.1265 (df = 1) |
| M1 | 28 (15.1%) | 4 (8.2%) | 37 (11.7%) | 80 (24.5%) | 5 (62.5%) | P = 0.0422 |
| Gleason score | ||||||
| 2-6 | 34 (18.3%) | 22 (31.9%) | 126 (39.8%) | 71 (23.5%) | 1 (12.5%) | 2.839 (df = 2) |
| 7 | 108 (58.0%) | 33 (47.8%) | 98 (30.9%) | 95 (31.5%) | 1 (12.5%) | P = 0.2418 |
| 8-10 | 44 (23.7%) | 14 (20.3%) | 93 (29.3%) | 136 (45.0%) | 6 (75.0%) | |
| PSA (ng/ml) | ||||||
| <10 | 110 (59.1%) | 41 (49.4%) | 142 (44.8%) | 29 (34.1%) | 0 (0.0%) | 2.253 (df = 2) |
| 10-20 | 57 (30.7%) | 21 (25.3%) | 102 (32.2%) | 8 (9.4%) | 0 (0.0%) | P = 0.3241 |
| >20 | 19 (10.2%) | 21 (25.3%) | 73 (23.0%) | 48 (56.5%) | 3 (100%) | |
| Jewett-Whitmore system | ||||||
| A | 35 (10.7%) | 0 (0.0%) | 7.3884 (df = 3) | |||
| B | ND | ND | ND | 126 (38.4%) | 1 (12.5%) | P = 0.0605 |
| C | 67 (20.4%) | 1 (12.5%) | ||||
| D | 100 (30.5%) | 6 (75.0%) | ||||
| Tumor grade | ||||||
| Well | 25 (7.9%) | 9 (3.0%) | 0 (0.0%) | 0.6087 (df = 2) | ||
| Moderate | ND | ND | 101 (31.9%) | 62 (20.5%) | 1 (12.5%) | P = 0.7376 |
| Poor | 191 (60.3%) | 231 (76.5%) | 7 (87.5%) |
*Data of Asan Medical Center, Korea; ** Data of National Cancer Center, Korea; *** Pearson's Chi-squared test was performed between total cases with prostate cancer and cases with rare alleles used in this study.